4.6 Review

Clinical management of the uraemic syndrome in chronic kidney disease

期刊

LANCET DIABETES & ENDOCRINOLOGY
卷 4, 期 4, 页码 360-373

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(16)00033-4

关键词

-

资金

  1. Nipro
  2. Bayer
  3. Fresenius Medical Care
  4. Pharmacosmos
  5. Amgen
  6. Genzyme
  7. Shire
  8. Servier

向作者/读者索取更多资源

The clinical picture of the uraemic syndrome is a complex amalgam of accelerated ageing and organ dysfunction, which progress in parallel to chronic kidney disease. The uraemic syndrome is associated with cardiovascular disease, metabolic bone disease, inflammation, protein energy wasting, intestinal dysbiosis, anaemia, and neurological and endocrine dysfunction. In this Review, we summarise specific, modern management options for the uraemic syndrome in chronic kidney disease. Although large randomised controlled trials are scarce, based on data from randomised controlled trials and observational studies, as well as pathophysiological reasoning, a therapeutic algorithm can be developed for this complex and multifactorial condition, with interventions targeting several modifiable factors simultaneously.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据